Saturday, May 31, 2025

Latest

Psyched Wellness Launches Study On Mushroom Extract Focused On Gut Health

Psyched Wellness (CSE: PSYC) this morning issued a very brief press release related to ongoing studies. The firm has initiated yet another study on its proprietary AME-1 extract, this time with the study focused on gut health.

To be conducted through the firms contract research organization, KGK Sciences, the study will look to further examine the anti-inflammatory nature of the firms Amanita Muscaria extract, AME-1. Effectively, the study is to advance the preliminary findings that identified the extract as having such anti-inflammatory properties.

With respect to its anti-inflammatory properties, the research is to place an emphasis on gut health, whereby the compound will be examined for having properties that may enhance digestive barrier function and immunity. Such functions are impaired when gut health is damaged, which can lead to inflammation and chronic conditions. The study will lay groundwork for future preclinical research to be conducted by the company.

Psyched Wellness last traded at $0.295 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

ESGold Begins Concentration Tests Ahead Of First Production

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

Related News

Psyched Wellness Increases Bought Deal To $5.5 Million

Psyched Wellness (CSE: PSYC) has increased the size of its bought deal private placement as...

Monday, January 25, 2021, 07:09:05 AM

Psyched Wellness Begins Pre-Clinical Trials Of Amanita Muscaria Mushroom

Psyched Wellness (CSE: PSYC) this morning announced that it has commenced its pre-clinical trials of...

Wednesday, December 23, 2020, 08:02:43 AM

Psyched Wellness To Commence Trading Today

Psyched Wellness (CSE: PSYC) is the latest mushroom issue to hit the CSE, with the...

Thursday, October 22, 2020, 08:36:53 AM

Psyched Wellness Sees Amanita Muscaria Approved As Medicinal Organism By Health Canada

After more than a years worth of development work, Psyched Wellness (CSE: PSYC) this morning...

Wednesday, November 3, 2021, 08:10:25 AM

Psyched Wellness Signs Two Year Supply Agreement For Amanita Muscaria

Psyched Wellness (CSE: PSYC) this morning had a brief announcement. Within, the company revealed that...

Tuesday, May 4, 2021, 08:36:07 AM